Aurobindo Pharma arm Apitoria Pharma got a US FDA VAI rating for its Telangana API plant Unit II following a recent inspection.

Apitoria Pharma Private Limited is a wholly owned subsidiary of Hyderabad-based Aurobindo Pharma Limited.

The plant, called Unit II, sits in Sangareddy district. It makes active pharmaceutical ingredients, the base chemicals that go into medicines.

The US Food and Drug Administration sent the company an Establishment Inspection Report, which is its written verdict on the visit.

The rating is Voluntary Action Indicated, or VAI. In simple terms, inspectors may have flagged some issues, but none that call for formal action against the plant.

The inspection is now closed. After an inspection, the regulator usually uses one of three ratings.

No Action Indicated means nothing was found. Official Action Indicated can lead to warning letters. VAI sits in the middle.

The visit began on 7 September and ended on 15 September 2026. In a September update, the company told exchanges it would respond to the regulator’s observation within the given timeline.

The United States is a big market for Indian drugmakers, so every plant that clears an inspection matters to the business.

A closed file means the regulator is not asking for further action on this site. Other Apitoria sites have had recent checks too.

Unit IV finished a US FDA inspection with no observations in September, while Unit VI recorded three procedural observations in August.

Each plant gets its own rating, so one result does not decide another. The parent company’s latest numbers are also out.

For the second quarter, Aurobindo Pharma reported consolidated net profit of about ₹1,124 crore on revenue of roughly ₹10,263 crore.

The board has also declared an interim dividend of ₹7 per share, with 11 November as the record date.